Recent News

• 12.05.2025 - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 11.10.2025 - Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
• 11.08.2025 - Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
• 11.06.2025 - Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates
• 10.27.2025 - Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
• 10.14.2025 - H.C. Wainwright Genetic Medicines Virtual Conference
• 10.03.2025 - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 10.03.2025 - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 11.12.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.10.2025 - EX-99.1 EX-99.1
• 11.10.2025 - 8-K Current report
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2025 - 8-K Current report
• 11.06.2025 - EX-99.1 EX-99.1
• 11.04.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.29.2025 - 8-K Current report
• 10.27.2025 - 8-K Current report